vs
CARLISLE COMPANIES INC（CSL）与UNITED THERAPEUTICS Corp（UTHR）财务数据对比。点击上方公司名可切换其他公司
CARLISLE COMPANIES INC的季度营收约是UNITED THERAPEUTICS Corp的1.3倍（$1.1B vs $790.2M），UNITED THERAPEUTICS Corp净利率更高（46.1% vs 12.1%，领先34.0%），UNITED THERAPEUTICS Corp同比增速更快（7.4% vs -4.0%），UNITED THERAPEUTICS Corp自由现金流更多（$173.3M vs $-73.0M），过去两年UNITED THERAPEUTICS Corp的营收复合增速更高（8.0% vs -14.8%）
卡莱尔公司是专业建筑产品供应商，聚焦于提升建筑能效与稳固性，面向商业建筑领域生产销售单层屋面产品、质保系统及配套配件，旗下设有卡莱尔建筑材料、卡莱尔防水技术两大业务板块，产品涵盖防潮材料、屋面防护层等多个品类。
United Therapeutics是美国生物技术企业，专注开发包含异种移植在内的器官移植相关药物与技术，多款产品布局肺部疾病及器官制造赛道，双总部位于马里兰州银泉与北卡罗来纳州三角研究园，在美加多地设有研发及运营分支机构。
CSL vs UTHR — 直观对比
营收规模更大
CSL
是对方的1.3倍
$790.2M
营收增速更快
UTHR
高出11.4%
-4.0%
净利率更高
UTHR
高出34.0%
12.1%
自由现金流更多
UTHR
多$246.3M
$-73.0M
两年增速更快
UTHR
近两年复合增速
-14.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $790.2M |
| 净利润 | $127.7M | $364.3M |
| 毛利率 | 34.5% | 86.9% |
| 营业利润率 | 17.1% | 45.1% |
| 净利率 | 12.1% | 46.1% |
| 营收同比 | -4.0% | 7.4% |
| 净利润同比 | -10.9% | 20.9% |
| 每股收益（稀释后） | $3.10 | $7.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSLUTHR
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $790.2M | ||
| Q3 25 | $1.3B | $799.5M | ||
| Q2 25 | $1.4B | $798.6M | ||
| Q1 25 | $1.1B | $794.4M | ||
| Q4 24 | $1.1B | $735.9M | ||
| Q3 24 | $1.3B | $748.9M | ||
| Q2 24 | $1.5B | $714.9M |
净利润CSLUTHR
| Q1 26 | $127.7M | — | ||
| Q4 25 | $127.4M | $364.3M | ||
| Q3 25 | $214.2M | $338.7M | ||
| Q2 25 | $255.8M | $309.5M | ||
| Q1 25 | $143.3M | $322.2M | ||
| Q4 24 | $162.8M | $301.3M | ||
| Q3 24 | $244.3M | $309.1M | ||
| Q2 24 | $712.4M | $278.1M |
毛利率CSLUTHR
| Q1 26 | 34.5% | — | ||
| Q4 25 | 33.8% | 86.9% | ||
| Q3 25 | 36.0% | 87.4% | ||
| Q2 25 | 37.3% | 89.0% | ||
| Q1 25 | 35.2% | 88.4% | ||
| Q4 24 | 36.1% | 89.7% | ||
| Q3 24 | 38.6% | 88.9% | ||
| Q2 24 | 39.2% | 89.1% |
营业利润率CSLUTHR
| Q1 26 | 17.1% | — | ||
| Q4 25 | 16.8% | 45.1% | ||
| Q3 25 | 21.8% | 48.6% | ||
| Q2 25 | 23.1% | 45.6% | ||
| Q1 25 | 16.8% | 48.2% | ||
| Q4 24 | 19.9% | 48.6% | ||
| Q3 24 | 23.7% | 45.8% | ||
| Q2 24 | 26.0% | 44.7% |
净利率CSLUTHR
| Q1 26 | 12.1% | — | ||
| Q4 25 | 11.3% | 46.1% | ||
| Q3 25 | 15.9% | 42.4% | ||
| Q2 25 | 17.6% | 38.8% | ||
| Q1 25 | 13.1% | 40.6% | ||
| Q4 24 | 14.5% | 40.9% | ||
| Q3 24 | 18.3% | 41.3% | ||
| Q2 24 | 49.1% | 38.9% |
每股收益（稀释后）CSLUTHR
| Q1 26 | $3.10 | — | ||
| Q4 25 | $3.06 | $7.66 | ||
| Q3 25 | $4.98 | $7.16 | ||
| Q2 25 | $5.88 | $6.41 | ||
| Q1 25 | $3.20 | $6.63 | ||
| Q4 24 | $3.76 | $6.23 | ||
| Q3 24 | $5.25 | $6.39 | ||
| Q2 24 | $14.84 | $5.85 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $771.3M | $2.9B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.7B | $7.1B |
| 总资产 | — | $7.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSLUTHR
| Q1 26 | $771.3M | — | ||
| Q4 25 | $1.1B | $2.9B | ||
| Q3 25 | $1.1B | $2.8B | ||
| Q2 25 | $68.4M | $3.0B | ||
| Q1 25 | $220.2M | $3.3B | ||
| Q4 24 | $753.5M | $3.3B | ||
| Q3 24 | $1.5B | $3.3B | ||
| Q2 24 | $1.7B | $3.0B |
总债务CSLUTHR
| Q1 26 | — | — | ||
| Q4 25 | $2.9B | — | ||
| Q3 25 | $2.9B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $1.9B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.3B | — |
股东权益CSLUTHR
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.8B | $7.1B | ||
| Q3 25 | $2.0B | $6.6B | ||
| Q2 25 | $2.1B | $7.2B | ||
| Q1 25 | $2.2B | $6.8B | ||
| Q4 24 | $2.5B | $6.4B | ||
| Q3 24 | $2.8B | $6.1B | ||
| Q2 24 | $3.0B | $5.7B |
总资产CSLUTHR
| Q1 26 | — | — | ||
| Q4 25 | $6.3B | $7.9B | ||
| Q3 25 | $6.5B | $7.4B | ||
| Q2 25 | $5.5B | $7.9B | ||
| Q1 25 | $5.5B | $7.7B | ||
| Q4 24 | $5.8B | $7.4B | ||
| Q3 24 | $6.5B | $7.1B | ||
| Q2 24 | $6.7B | $6.7B |
负债/权益比CSLUTHR
| Q1 26 | — | — | ||
| Q4 25 | 1.61× | — | ||
| Q3 25 | 1.45× | — | ||
| Q2 25 | 0.89× | — | ||
| Q1 25 | 0.87× | — | ||
| Q4 24 | 0.77× | — | ||
| Q3 24 | 0.83× | — | ||
| Q2 24 | 0.76× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $346.2M |
| 自由现金流经营现金流 - 资本支出 | $-73.0M | $173.3M |
| 自由现金流率自由现金流/营收 | -6.9% | 21.9% |
| 资本支出强度资本支出/营收 | 2.7% | 21.9% |
| 现金转化率经营现金流/净利润 | — | 0.95× |
| 过去12个月自由现金流最近4个季度 | $924.8M | $1.0B |
8季度趋势，按日历期对齐
经营现金流CSLUTHR
| Q1 26 | — | — | ||
| Q4 25 | $386.0M | $346.2M | ||
| Q3 25 | $426.9M | $562.1M | ||
| Q2 25 | $287.1M | $191.7M | ||
| Q1 25 | $1.8M | $461.2M | ||
| Q4 24 | $370.6M | $341.2M | ||
| Q3 24 | $312.8M | $377.2M | ||
| Q2 24 | $183.4M | $232.2M |
自由现金流CSLUTHR
| Q1 26 | $-73.0M | — | ||
| Q4 25 | $346.1M | $173.3M | ||
| Q3 25 | $393.4M | $351.6M | ||
| Q2 25 | $258.3M | $129.5M | ||
| Q1 25 | $-27.2M | $386.3M | ||
| Q4 24 | $334.0M | $254.5M | ||
| Q3 24 | $293.5M | $300.7M | ||
| Q2 24 | $158.5M | $187.1M |
自由现金流率CSLUTHR
| Q1 26 | -6.9% | — | ||
| Q4 25 | 30.7% | 21.9% | ||
| Q3 25 | 29.2% | 44.0% | ||
| Q2 25 | 17.8% | 16.2% | ||
| Q1 25 | -2.5% | 48.6% | ||
| Q4 24 | 29.7% | 34.6% | ||
| Q3 24 | 22.0% | 40.2% | ||
| Q2 24 | 10.9% | 26.2% |
资本支出强度CSLUTHR
| Q1 26 | 2.7% | — | ||
| Q4 25 | 3.5% | 21.9% | ||
| Q3 25 | 2.5% | 26.3% | ||
| Q2 25 | 2.0% | 7.8% | ||
| Q1 25 | 2.6% | 9.4% | ||
| Q4 24 | 3.3% | 11.8% | ||
| Q3 24 | 1.4% | 10.2% | ||
| Q2 24 | 1.7% | 6.3% |
现金转化率CSLUTHR
| Q1 26 | — | — | ||
| Q4 25 | 3.03× | 0.95× | ||
| Q3 25 | 1.99× | 1.66× | ||
| Q2 25 | 1.12× | 0.62× | ||
| Q1 25 | 0.01× | 1.43× | ||
| Q4 24 | 2.28× | 1.13× | ||
| Q3 24 | 1.28× | 1.22× | ||
| Q2 24 | 0.26× | 0.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSL
| CCM | $758.0M | 72% |
| CWT | $294.0M | 28% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
